ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 408,64
-0,30%
Dow Jones
42 297,12
0,86%
DAX
20 132,85
-0,44%
Brent Oil
80,165
-0,14%
Bitcoin
94 685,34
0,19%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Connect Biopharma Holdings Inc (CNTB) Cours

Connect Biopharma Holdings Inc

Connect Biopharma Holdings Inc (CNTB)

NASDAQ
1,0856
0,0056
(0,52%)
Fermé 14 Janvier 10:00PM
Retardé de 15 minutes
1,0856
0,00
(0,00%)
Après les heures de négociation: 10:02PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
1,0856
Prix Achat
1,03
Prix Vente
1,10
Volume échangé
46 648
1,04 Fourchette du Jour 1,095
0,00 Plage de 52 semaines 0,00
Cap du marché
59,82M
Clôture Veille
1,08
Ouverture
1,09
Dernière Transaction
2
@
1.09
Dernière heure de transaction
Volume financier
US$ 49 225
VWAP
1,0552
Volume moyen (3 m)
-
Actions en circulation
55 102 954
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-
Chiffre d'affairess
1,58M
Bénéfice net
-59,5M

À propos de Connect Biopharma Holdings Inc

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug ... Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Grand Cayman, Cym
Fondé
-
Connect Biopharma Holdings Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CNTB. Le dernier cours de clôture d'Connect Biopharma était de US$1,08. Au cours de la dernière année, les actions de Connect Biopharma ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Connect Biopharma compte actuellement 55 102 954 actions en circulation. La capitalisation boursière d'Connect Biopharma est de US$59,51 million.

CNTB Dernières nouvelles

Plus de nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

23 Décembre 2024
Edgar (US Regulatory)

Attovia Therapeutics Appoints Chief Financial Officer

FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...

15 Octobre 2024
GlobeNewswire Inc.

Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

SAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage...

10 Septembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

06 Septembre 2024
Edgar (US Regulatory)

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect’s new management is currently evaluating...

05 Septembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

02 Août 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

12 Juin 2024
Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

28 Février 2024
Edgar (US Regulatory)

Form SC 13D - General statement of acquisition of beneficial ownership

13 Février 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

13 Février 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

CNTB - Frequently Asked Questions (FAQ)

What is the current Connect Biopharma share price?
The current share price of Connect Biopharma is US$ 1,0856
How many Connect Biopharma shares are in issue?
Connect Biopharma has 55 102 954 shares in issue
What is the market cap of Connect Biopharma?
The market capitalisation of Connect Biopharma is USD 59,51M
What is the 1 year trading range for Connect Biopharma share price?
Connect Biopharma has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the reporting currency for Connect Biopharma?
Connect Biopharma reports financial results in USD
What is the latest annual turnover for Connect Biopharma?
The latest annual turnover of Connect Biopharma is USD 1,58M
What is the latest annual profit for Connect Biopharma?
The latest annual profit of Connect Biopharma is USD -59,5M
What is the registered address of Connect Biopharma?
The registered address for Connect Biopharma is P.O. BOX 613, HARBOUR CENTRE, GEORGE TOWN, GRAND CAYMAN, KY1-1107
Which industry sector does Connect Biopharma operate in?
Connect Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
SLRXSalarius Pharmaceuticals Inc
US$ 3,65
(133,23%)
120,26M
VRMEVerifyMe Inc
US$ 4,1575
(63,04%)
57,6M
ATPCAgape ATP Corporation
US$ 1,9645
(55,91%)
84,16M
AVGRAvinger Inc
US$ 0,8248
(46,47%)
9,78M
EHGOEshallgo Inc
US$ 1,2408
(-62,06%)
6,74M
CMTLComtech Telecommunications Corporation
US$ 2,3491
(-43,12%)
4,37M
SVMHSRIVARU Holding Ltd
US$ 0,0352
(-43,04%)
184,27M
LAESSEALSQ Corporation
US$ 3,35
(-41,54%)
89,92M
NMHINatures Miracle Holding Inc
US$ 1,12
(-38,80%)
735,08k
GCTKGlucoTrack Inc
US$ 0,1493
(27,61%)
685,02M
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0627
(-28,83%)
232,25M
NVDANVIDIA Corporation
US$ 133,23
(-1,97%)
204,68M
RGTIRigetti Computing Inc
US$ 6,0344
(-32,43%)
192,21M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CNTB
Connect Biopharma
BIT
P1T8L0
BNP Paribas Issuance
BIT
S28762
Societe Generale Effekten
BIT
WINA
Exchange Traded
BIT
P1NA13
BNP Paribas Issuance
TSX
SOT.DB.B
Slate Office REIT
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés